Baloxavir Marboxil
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Baloxavir Marboxil |
| DrugBank ID | DB13997 |
| Brand Names (EU) | Xofluza |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.56% |
Approved Indication (EMA)
Treatment of influenza Xofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. Post exposure prophylaxis of influenza Xofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. Xofluza should be used in accordance with official recommendations.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | influenza, severe, susceptibility to | 99.56% | DL |
| 2 | acquired hemophagocytic lymphohistiocytosis associated with malignant disease | 98.85% | DL |
| 3 | hemophagocytic syndrome associated with an infection | 98.85% | DL |
| 4 | influenza | 98.65% | DL |
| 5 | cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency | 98.55% | DL |
| 6 | Singleton-Merten syndrome | 97.81% | DL |
| 7 | hemophagocytic syndrome | 94.97% | DL |
| 8 | chronic hepatitis C virus infection | 94.95% | DL |
| 9 | hepatitis C virus infection | 93.26% | DL |
| 10 | hepatitis E virus infection | 92.53% | DL |
| 11 | hepatitis A virus infection | 92.42% | DL |
| 12 | Omsk hemorrhagic fever | 92.00% | DL |
| 13 | Kyasanur forest disease | 91.81% | DL |
| 14 | hepatitis, viral, animal | 91.63% | DL |
| 15 | hepatitis B virus infection | 89.74% | DL |
| 16 | pyelonephritis | 87.98% | DL |
| 17 | squamous cell lung carcinoma | 84.97% | DL |
| 18 | mendelian susceptibility to mycobacterial diseases due to complete ISG15 deficiency | 84.13% | DL |
| 19 | A20 haploinsufficiency | 82.74% | DL |
| 20 | immune dysregulation with inflammatory bowel disease | 82.07% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.